🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSurvodutide (GCG/GLP-1) — MASH and obesity trial results Page 4

Survodutide (GCG/GLP-1) — MASH and obesity trial results

MASHdoc_SA Sat, Jun 6, 2026 at 8:40 PM 16 replies 467 viewsPage 4 of 4
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jun 7, 2026 at 2:20 AM#16

Congrats JennaRN!! Keep going — you're doing incredible. 🎉

Last edited: Jun 7, 2026 at 7:20 AM
25 14paul_denver, TinaHashiRN, robert_kc and 22 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Jun 7, 2026 at 2:37 AM#17

Just wanted to say — for anyone reading this Survodutide thread who is feeling discouraged: it gets better. The first 6 weeks are the hardest. Hang in there. 💪

24 1anna.melb_AU, mark_tokyo, hans_munich and 21 others
Reply Quote Save Share Report
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Jun 7, 2026 at 2:54 AM#18

Can confirm — my data shows the same pattern.

23 18robert_kc, dan_philly, MeganSA_TX and 20 others
Reply Quote Save Share Report
steph_laguna
Member
234
1,123
Nov 2024
Laguna Beach, CA
Jun 7, 2026 at 3:11 AM#19

+1 to B12Beth. Especially the point about "Saving this for reference..." — I have seen the same in my own experience with Survodutide (GCG/GLP-1) .

Last edited: Jun 7, 2026 at 9:11 AM
25 0DanielChem_CHI, marco_milano, pam_columbus and 22 others
Reply Quote Save Share Report
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Jun 7, 2026 at 3:28 AM#20

Subscribing to this thread. Survodutide (GCG/GLP-1) is exactly what I've been researching. 🙏

36 13sarah.morrison, NeuroNate, JessicaH_TX and 33 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register